EYEGENE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,150 KRW | -1.10% |
|
-1.41% | -26.14% |
| Sales 2022 | 5.29B 3.84M | Sales 2023 | 3.13B 2.27M | Capitalization | 91.61B 66.51M |
|---|---|---|---|---|---|
| Net income 2022 | -25.95B -18.84M | Net income 2023 | -21.11B -15.32M | EV / Sales 2022 | 8.31 x |
| Net cash position 2022 | 64.06B 46.51M | Net cash position 2023 | 52.16B 37.87M | EV / Sales 2023 | 12.6 x |
| P/E ratio 2022 |
-4.16
x | P/E ratio 2023 |
-4.37
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.98% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.10% | ||
| 1 week | -1.41% | ||
| Current month | -7.08% | ||
| 1 month | +1.45% | ||
| 3 months | -7.22% | ||
| 6 months | -9.74% | ||
| Current year | -26.14% |
1 week
3 050.00
3 275.00
1 month
3 050.003 500.00
Current year
2 935.004 415.00
1 year
2 800.004 895.00
3 years
2 800.0060 200.00
5 years
2 800.0060 200.00
10 years
2 800.0060 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Won-Il Yoo
CEO | Chief Executive Officer | 60 | 00-06-22 |
Myeong-Jae Rhee
DFI | Director of Finance/CFO | 54 | 12-04-30 |
Yang-Je Cho
CTO | Chief Tech/Sci/R&D Officer | 55 | 00-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Doo Choi
AUD | Comptroller/Controller/Auditor | 54 | 12-02-29 |
Won-Il Yoo
CEO | Chief Executive Officer | 60 | 00-06-22 |
Yang-Je Cho
CTO | Chief Tech/Sci/R&D Officer | 55 | 00-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3,150 | -1.10% | 35 722 |
| 24-04-18 | 3,185 | +0.79% | 29,983 |
| 24-04-17 | 3,160 | 0.00% | 44,743 |
| 24-04-16 | 3,160 | +0.80% | 50,443 |
| 24-04-15 | 3,135 | -1.72% | 53,273 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Companyâs products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.14% | 62.54M | |
| +24.99% | 672B | |
| +24.08% | 550B | |
| -6.35% | 351B | |
| +15.04% | 317B | |
| +7.35% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -10.51% | 144B | |
| -7.45% | 141B |
- Stock Market
- Equities
- A185490 Stock
